You are viewing the site in preview mode

Skip to main content

Advertisement

You are viewing the new BMC article page. Let us know what you think. Return to old version

Poster presentation | Open | Published:

Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma

Background

Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.

Methods

Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.

Results

87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).

Conclusion

Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.

Table 1 Clinicopathological characteristics of the HCC patients

Author information

Correspondence to Meng Wang.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Hepatocellular Carcinoma
  • Reverse Transcription Polymerase Chain Reaction
  • Clinicopathological Parameter
  • Cancer Immunotherapy
  • Testis Antigen